The MMRF Blog - Multiple Myeloma Research Foundation

The MMRF Blog

Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma.

Liu L, Zhao N, Xu W, Sheng Z, Wang L. J Hematol Oncol. 2016 Jul 12;9(1):54. doi: 10.1186/s13045-016-0286-x. PMID: 27405295 [PubMed - in process] Free PMC Article READ MORE

Posted: July 21, 2016

T cells expressing an anti-B-cell-maturation-antigen chimeric antigen receptor cause remissions of multiple myeloma.

Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, Brudno JN, Stetler-Stevenson M, Feldman SA, Hansen BG, Fellowes VS, Hakim FT, Gress RE, Kochenderfer JN. Blood. 2016 Jul 13. pii: blood-2016-04-711903. [Epub ahead of print] PMID: 27412889 [PubMed - as supplied by publisher] READ MORE

Posted: July 21, 2016

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).

Hájek R, Masszi T, Petrucci MT, Palumbo A, Rosiñol L, Nagler A, Yong KL, Oriol A, Minarik J, Pour L, Dimopoulos MA, Maisnar V, Rossi D, Kasparu H, Van Droogenbroeck J, Yehuda DB, Hardan I, Jenner M, Calbecka M, Dávid M, de la Rubia J, Drach J, Gasztonyi Z, Górnik S, Leleu X, Munder M, Offidani M, Zojer N, Rajangam K, Chang YL, San-Miguel JF, Ludwig H. Leukemia. 2016 Jul 15. doi: 10.1038/leu.2016.176. [Epub ahead of print] PMID: 27416912 [PubMed - as supplied by publisher] READ MORE

Posted: July 21, 2016

Page 17 of 87« First...10...1516171819...304050...Last »